Huiyu Pharmaceuticals (688553.SH) subsidiary's application for clinical trial of HY07121 (subcutaneous injection) has been accepted.

Intelligently Financial APP News, Huayu Pharmaceutical (688553.SH) announced that recently, its wholly-owned subsidiary Sichuan Huayu Haiyue Medical Technology Co., Ltd. received the "Acceptance Notice" issued by the National Medical Products Administration for the clinical trial application of injection HY07121 (subcutaneous injection)(project research and development code "HY0007") for the treatment of advanced solid tumors. The drug is expected to be approved for intravenous administration in September 2024, and is currently in phase I clinical trial.